|
1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7-30. 2.Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Annals of oncology : official journal of the European Society for Medical Oncology. Apr 2016;27(4):725-731. 3.Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. Mar 2015;65(2):87-108. 4.Polyak K. Breast cancer: origins and evolution. The Journal of clinical investigation. Nov 2007;117(11):3155-3163. 5.Sylvester RK. Breast Cancer. In: Sutton SS, ed. McGraw-Hill''s NAPLEX® Review Guide, 2e. New York, NY: McGraw-Hill Education; 2014. 6.Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England journal of medicine. Feb 19 2015;372(8):724-734. 7.Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine. Nov 8 2012;367(19):1783-1791. 8.Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast (Edinburgh, Scotland). Oct 2014;23(5):489-502. 9.Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. Sep 19 2013;501(7467):328-337. 10.Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jan 1 2010;28(1):92-98. 11.Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Nov 1 2013;31(31):3997-4013. 12.Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nature reviews. Molecular cell biology. Jul 2006;7(7):505-516. 13.Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature medicine. Oct 2002;8(10):1153-1160. 14.Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature reviews. Drug discovery. Aug 2009;8(8):627-644. 15.Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. The Cochrane database of systematic reviews. Jun 12 2014(6):Cd006242. 16.Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine. Mar 15 2001;344(11):783-792. 17.Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clinical breast cancer. Aug 2005;6(3):240-246. 18.Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Sep 1999;17(9):2639-2648. 19.Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jul 1 2005;23(19):4265-4274. 20.Spector NL, Xia W, Burris H, 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Apr 10 2005;23(11):2502-2512. 21.Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology. May 2013;14(6):461-471. 22.Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast cancer research and treatment. Jul 2011;128(2):347-356. 23.Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer research. Nov 15 2008;68(22):9280-9290. 24.Burris HA, 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Feb 1 2011;29(4):398-405. 25.Dzimitrowicz H, Berger M, Vargo C, et al. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Oct 10 2016;34(29):3511-3517. 26.Reeder CE. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. Oct 1 1995;52(19 Suppl 4):S5-8. 27.Dusetzina SB. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014. JAMA oncology. Jul 1 2016;2(7):960-961. 28.Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Mar 20 2013;31(9):1157-1163. 29.Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician''s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet. Oncology. Jun 2014;15(7):689-699. 30.Shen K, Ma X, Zhu C, et al. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. Scientific reports. Mar 16 2016;6:23262. 31.Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. Jul 21 2009;6(7):e1000097. 32.Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration''s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). Oct 18 2011;343:d5928. 33.Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Mar-Apr 2013;16(2):231-250. 34.Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. Jun 7 2007;8:16. 35.Dieras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet. Oncology. Jun 2017;18(6):732-742. 36.Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician''s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. The Lancet. Oncology. Jun 2017;18(6):743-754. 37.Perez EA, Barrios C, Eiermann W, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jan 10 2017;35(2):141-148. 38.Diaby V, Adunlin G, Ali AA, et al. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment. Nov 2016;160(1):187-196. 39.Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast cancer research and treatment. Oct 2016;159(3):565-573. 40.Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.). Sep 13 1997;315(7109):629-634. 41.Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clinical research ed.). Jul 22 2011;343:d4002. 42.Ma B, Ma Q, Wang H, et al. Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer. OncoTargets and therapy. 2016;9:959-976. 43.Deeks JJ, Higgins JPT, DG A. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. updated March 2011;The Cochrane Collaboration, 2011. 44.Yu Q, Zhu Z, Liu Y, et al. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. PloS one. 2015;10(5):e0127404. 45.Welslau M, Dieras V, Sohn JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. Mar 1 2014;120(5):642-651.
|